Sign up
Pharma Capital

VolitionRx well funded as it advances development of its novel cancer tests

VolitionRx Limited (NYSEAmerican:VNRX) CEO Cameron Reynolds brings Proactive's Andrew Scott up to date on developments with their cancer blood tests as well as discussing the group's 2018 results.

As of the end of December, Volition's cash position stood at $13.4 million - up from $10.1 million at the close of 2017.

Reynolds says continued development of their Nu.Q Capture and Nu.Q Vet products coupled with the strengthening of the company's product pipeline beyond colorectal cancer will help them generate early revenue.


View full VNRX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.